International Journal of Pharmaceutical Compounding

A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of all issues and individual articles published by the Journal since 1997.

LEARN MORE

PreScription: First Estriol, Then What?

Author(s): Allen Loyd V Jr

Issue: Jul/Aug 2008 - Hormone Replacement Therapy
View All Articles in Issue

Page(s): 284

PreScription: First Estriol, Then What? Page 1

Download in electronic PDF format for $75

Abstract:

Related Keywords: U.S. Food and Drug Administration, FDA, estriol, regulation, Wyeth, hormone replacement therapy, drug safety

Related Categories: HRT, LEGAL, ADVERSE DRUG EVENTS, ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE, PROFESSIONAL ISSUES

Printer-Friendly Version

Title/Author (Click for Abstract / Details / Purchase)	Issue/Page View/Buy
Related Articles from IJPC
PreScription: First Estriol, Then What? Allen Loyd V Jr	Jul/Aug 2008 Pg. 284
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Allen Loyd V Jr	Sep/Oct 2017 Pg. 356
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Allen Loyd V Jr	Jul/Aug 2016 Pg. 351 View Sample
The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Stephenson Kenna, Jones William, Stephenson Douglas M M	May/Jun 2006 Pg. 175-183
The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Brunner Scott	Jan/Feb 2023 Pg. 22-23
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Miller David G	Jul/Aug 2015 Pg. 303-305
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs Allen Loyd V Jr	Nov/Dec 2015 Pg. 487-488
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies Yoch Doug	Mar/Apr 2017 Pg. 95-102
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A	Jan/Feb 2019 Pg. 32-33
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed Brunner Scott	Jul/Aug 2020 Pg. 296-297
Estriol: Women's Choice vs. A Manufacturer's Greed Goodrum Jennifer	Jul/Aug 2008 Pg. 286-292
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter Miller David G	May/Jun 2014 Pg. 208
Standard Operating Procedure: U.S. Food and Drug Administration Inspection--Releasing a Sample to the U.S. Food and Drug Administration Kupiec Tom, Kemp Jesse	Jul/Aug 2007 Pg. 326-327
Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2 Ford Gina, Garcia Lea	Jan/Feb 2001 Pg. 52-54
U.S. Food and Drug Administration List of Drugs NOT to be Used in Compounded Medications for Humans (The Negative List)	Nov/Dec 2016 Pg. 457-458
A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1 Gillson George R, Zava David T	Jul/Aug 2003 Pg. 250-256
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1 Allen Loyd V Jr	Sep/Oct 2015 Pg. 389-390
U.S. Food and Drug Administration Requests for Input on HR 3204 Enactment: The Drug Quality and Security Act of 2013 Miller David G	Jan/Feb 2014 Pg. 35-36
Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety Allen W Chris, Greeson Nicole MH, Mixon William	Nov/Dec 2020 Pg. 451-458
Major Study Affirming the Relative Safety of Testosterone-replacement Therapy Biundo Bruce	Sep/Oct 2023 Pg. 358-360
Return to Top